Verrica Pharmaceuticals Inc (NASDAQ:VRCA) — Market Cap & Net Worth
Market Cap & Net Worth: Verrica Pharmaceuticals Inc (VRCA)
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) has a market capitalization of $79.88 Million ($79.88 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20167 globally and #4590 in its home market, demonstrating a -8.10% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Verrica Pharmaceuticals Inc's stock price $4.65 by its total outstanding shares 17178786 (17.18 Million). Also see balance sheet size of Verrica Pharmaceuticals Inc for a full breakdown of the balance sheet.
Verrica Pharmaceuticals Inc Market Cap History: 2018 to 2026
Verrica Pharmaceuticals Inc's market capitalization history from 2018 to 2026. Data shows change from $140.01 Million to $79.88 Million (-14.82% CAGR). Also see VRCA cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Verrica Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #576 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1938 of 3165 |
Weight: Verrica Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Verrica Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Verrica Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Verrica Pharmaceuticals Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.01x
Verrica Pharmaceuticals Inc's market cap is 4.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $197.73 Million | $12.00 Million | -$45.50 Million | 16.48x | N/A |
| 2021 | $157.36 Million | $12.00 Million | -$35.08 Million | 13.11x | N/A |
| 2022 | $47.24 Million | $9.03 Million | -$24.49 Million | 5.23x | N/A |
| 2023 | $125.75 Million | $5.12 Million | -$67.00 Million | 24.54x | N/A |
| 2024 | $12.03 Million | $7.57 Million | -$76.58 Million | 1.59x | N/A |
| 2025 | $142.76 Million | $35.58 Million | -$17.89 Million | 4.01x | N/A |
Competitor Companies of VRCA by Market Capitalization
Companies near Verrica Pharmaceuticals Inc in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Verrica Pharmaceuticals Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Verrica Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Verrica Pharmaceuticals Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Verrica Pharmaceuticals Inc's market cap moved from $140.01 Million to $ 79.88 Million, with a yearly change of -14.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $79.88 Million | -44.04% |
| 2025 | $142.76 Million | +1087.14% |
| 2024 | $12.03 Million | -90.44% |
| 2023 | $125.75 Million | +166.18% |
| 2022 | $47.24 Million | -69.98% |
| 2021 | $157.36 Million | -20.42% |
| 2020 | $197.73 Million | -27.56% |
| 2019 | $272.97 Million | +94.97% |
| 2018 | $140.01 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Verrica Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $79.88 Million USD |
| MoneyControl | $79.88 Million USD |
| MarketWatch | $79.88 Million USD |
| marketcap.company | $79.88 Million USD |
| Reuters | $79.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the tr… Read more